Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9HCS2

UPID:
CP4FC_HUMAN

ALTERNATIVE NAMES:
CYPIVF12

ALTERNATIVE UPACC:
Q9HCS2; E7ET51; O60389; Q5JPJ7; Q9HCS1

BACKGROUND:
The enzyme Cytochrome P450 4F12, also known as CYPIVF12, is integral to the metabolism of endogenous substances and xenobiotics. It efficiently processes polyunsaturated fatty acids (PUFAs) by hydroxylating carbon hydrogen bonds and epoxidizing double bonds, with a notable activity towards arachidonate and its conversion to 18-hydroxy arachidonate. Additionally, it metabolizes the antihistamine ebastine, showcasing its versatility in drug metabolism.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cytochrome P450 4F12's functions offers a promising avenue for developing novel therapeutic approaches, especially in the areas of PUFA metabolism regulation and the enhancement of drug metabolism processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.